Contract facts
FederalBPA FOR PLUVICTO AND LUTATHERA INJECTION is a federal award for Defense Health Agency Hcd West held by Novartis Pharmaceuticals Corp. Estimated value —.
Incumbent footprint
Public recordNovartis Pharmaceuticals Corp — $23.5M obligated across 59 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract HT941026AE002?
HT941026AE002 (BPA for pluvicto and lutathera injection) is a Defense Health Agency Hcd West award with an estimated value of —, currently held by Novartis Pharmaceuticals Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded HT941026AE002?
Defense Health Agency Hcd West awarded HT941026AE002 to Novartis Pharmaceuticals Corp.
Who is the incumbent on HT941026AE002?
Novartis Pharmaceuticals Corp is the incumbent with $23.5M across 59 related awards in SCOUT’s public footprint.
When does Novartis Pharmaceuticals Corp’s HT941026AE002 come up for recompete?
SCOUT tracks a period-of-performance end of an unstated date. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.